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Abstract
Background: Human noroviruses (NoVs) are the main cause of non-bacterial gastroenteritis worldwide. Several
studies have linked human susceptibility to NoVs with the expression of histo-blood group antigens (HBGAs). In
January 2012, a NoV gastroenteritis outbreak affected a household in Valencia, Spain, and the personal susceptibility
to NoV was investigated.
Methods: To reach this aim 8 members of the affected household were recruited for this study and their secretor
status, ABO and Lewis antigens were determined. NoV-specific saliva IgA and serum IgG antibody titers were
analyzed. Their capacity to block viral binding to saliva receptors was analyzed, using virus-like particles (VLPs) of
the NoV GII.4 genotype, 2006b variant, and saliva from a secretor O blood type donor.
Results: The most relevant finding was that an asymptomatic non-secretor individual shed NoVs in his stools.
Interestingly, anti-NoV IgA antibody titers in saliva from secretor and non-secretor individuals showed no differences.
On the contrary, high titers of NoV-specific IgG antibody were found in both convalescent sera and in sera collected
1 year post-infection, but only from secretor individuals. NoV GII.4-2006b VLP binding to receptors present in the saliva
was efficiently blocked only by sera from secretor positive individuals.
Conclusions: Despite the small number of individuals involved in this outbreak, this study reinforces the idea that
susceptibility to human NoV is both dependent on the HBGA profile of the individuals as well as on the viral genotype
and variant. We also show that the immunity to NoV lasts for at least 1 year after infection, demonstrating that
symptomatic infections strongly stimulate immune responses.
Keywords: Norovirus, Susceptibility, Histo-blood group antigens, FUT2, Secretor, Virus-like particles, IgA, IgG,
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Background
Noroviruses (NoVs), members of the Caliciviridae fam-
ily, are small, positive-polarity RNA viruses and the most
important cause of human viral gastroenteritis world-
wide [1]. They are classified into 7 genogroups, although
genogroups I (GI) and GII cause most human NoV in-
fections [2]. These two genogroups are subdivided into 9
and 22 different genotypes, respectively. Several geno-
type GII.4 variants have emerged and caused the major-
ity of all NoV-associated gastroenteritis outbreaks and
sporadic infections over the past 2 decades [3]. It has
been shown that there are differences in NoV susceptibil-
ity in humans [4]. This different susceptibility is associated
to histo-blood group antigens (HBGAs) (i.e. the ABO
blood group, the Lewis phenotype and the secretor status)
[5] since NoVs recognize human histo-blood group anti-
gens [6–8].
The expression of the α-1,2-fucosyltransferase (FucT
II) enzyme, encoded by the FUT2 gene, determines the
secretor status of an individual [9]. Secretor positive in-
dividuals have A, B, H, Leb and/or Ley antigens. In con-
trast, secretor negative or non-secretor individuals have
an inactive FUT2, leading to the lack of A, B, H, Leb
and/or Ley antigens. However, they may be Lea and Lex
positive as products of FUT3 [10, 11]. The Lewis antigen
is determined by the expression of the α-1,3-fucosyl-
transferase (FucT III) enzyme encoded by FUT3. Homo-
zygous carriers of inactive FUT3 alleles lack Lea and Leb
structures, and such individuals are denoted Lewis-
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negative and constitute about 5 % of the Caucasian
population. In addition to HBGAs, intestinal microbiota
seems to have a role in susceptibility to NoV infection.
It was recently demonstrated that human NoV infection
can take place in vitro by using B cells as hosts and that
this infectivity is linked to the intestinal microbiota [12].
In agreement with these findings, murine NoV (MNoV)
infection in antibiotic-treated mice is reduced compared
with mice with normal intestinal microbiota. Microbiota
ablation with antibiotics also prevented persistent
MNoV infection in mice [13].
It has been previously shown that human susceptibility
to NoV is not completely determined by the secretor
status, since secretor negative individuals can also be in-
fected by NoVs [14, 15] spurring new studies to explore
other host factors implied in NoV susceptibility.
In January 2012 a NoV gastroenteritis outbreak took
place in a household in Valencia, Spain, that was a good
opportunity to study the different individual susceptibil-
ity patterns to this viral infection.
Methods
Subjects and samples
Eight individuals were enrolled in this study, none of
whom had taken any medication at or around the time
of sample collection. The biosafety and ethics commit-
tees of the University of Valencia, Spain, approved the
present study. Appropriate informed written consents
were obtained from all individuals. Of these, at least 4
subjects were in contact with the suspected source of in-
fection, a previously infected individual who was consid-
ered the index case, and three of them showed typical
symptoms of NoV infection (nausea, vomiting, diar-
rhoea, abdominal pain and fever). The family members
were living together and the outbreak was considered to
be person-to-person transmitted. In order to determine
the etiological agent of this outbreak, stool samples were
collected from involved individuals with and without
clinical symptoms. Serum samples from 3 household
members were collected at 14 days (considered conva-
lescent serum) and 1 year (considered memory serum)
post-infection to analyze NoV-specific IgG antibodies
and their blocking capacity. Blood samples were also col-
lected to determine the histo-blood group antigens of
each individual by hemagglutination. Saliva samples
from all the household members were collected. The
freshly collected saliva samples were centrifuged at
10,000 × g for 5 min to remove particulate material, host
and microbial cells and boiled at 100 °C to inactivate
antibodies. The supernatants were collected, divided into
several aliquots and stored at -80 °C until their use. To
minimize the effects of the circadian rhythm, saliva samples
were consistently collected in the morning hours (between
8 and 10 a.m.). Also, participants were instructed not to
smoke, eat, drink, or brush their teeth in the 2 h before sal-
iva collection. For genotyping and NoV-specific IgA anti-
body detection, saliva was centrifuged, divided into several
aliquots and stored directly at -80 °C without boiling to
preserve IgA integrity.
Norovirus detection
Viral RNA was extracted from 20 % stool suspensions in
PBS using the Trizol LS reagent (Invitrogen, Paisley,
Scotland), eluted in diethyl pyrocarbonate-treated water
containing RNasin (Promega, Madison, WI) and stored
at -80 °C. Reverse transcriptase-polymerase chain reac-
tion (RT-PCR) for NoV was performed as described
previously [16]. The genotype of NoV strains was deter-
mined by partial sequence analysis of the polymerase
gene and the genotype was identified and classified using
the typing tool at www.rivm.nl/mpf/norovirus/typingtool
based on the similarity of the sequences to reference
strains representing known genotypes [17].
Secretor status analysis
The secretor (FUT2+) and non-secretor (FUT2-) status
was investigated by genotyping the FUT2 gene. Genomic
DNA was extracted from saliva samples using the
Qiagen QIAamp DNA Mini Kit. Genotyping for FUT2
was performed by PCR-RFLP as described previously by
Marionneau et al. [18]. A fragment of the FUT2 gene
was amplified with primers 5′-GAGGAATACCGCCA
CATCCCGGGGGAGTAC-3′ (forward) and 5′-ATGGA
CCCCTACAAAGGTGCCCGGCCGGCT-3′ (reverse) and
was digested with Ava II (Fermentas, Life Technologies,
Alcobendas, Spain) for 2.5 h at 37 °C.
ABO blood type and Lewis antigen determination
The presence of HBGAs was determined by detection of
group A and B glycans by hemagglutination assay (ALBA-
clone® Monoclonal ABO Antisera, Alpha Laboratories,
Eastleigh, England) and Lewis antigens were phenotyped
by ELISA with monoclonal antibodies against Lea, Leb, Lex
and Ley (Covance, Dedham, MA, USA). Briefly, plates
were coated with saliva samples at 1/1,000 dilution in car-
bonate/bicarbonate buffer (pH 9.6) at 4 °C overnight. After
blocking with PBS containing 3 % (w/v) bovine seroalbu-
min (PBS-BSA), plates were incubated with the different
anti-Lewis antigen monoclonal antibodies (anti-Lea BG-5,
Leb BG-6, Lex BG-7 or Ley BG-3, Covance) at 1/100 dur-
ing 1 h at 37 °C and detected by a secondary mouse anti-
body mix (anti-IgG, anti-IgM and anti-IgA) (Sigma,
Madrid, Spain) conjugated to horseradish peroxidase
(HRP). After each step, plates were washed with PBS con-
taining 0.05 % of Tween-20 (PBS-T). The reaction was de-
veloped by the addition of OPD Fast (Sigma) and stopped
after 10 min incubation with 3 M H2SO4. Absorbance was
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measured at 492 nm in a microplate reader (Multiskan
FC, Thermo Scientific, Alcobendas, Madrid).
Norovirus VLPs
In the present study, VLPs corresponding to GII.4-Den
Haag_2006b genotype were used. The recombinant
baculovirus expressing the GII.4-2006b was already
available in the laboratory [19]. The NoV VLPs were
produced and purified as previously described [19]. Be-
cause VLPs from the GII.4-New Orleans_2009 variant
causing the NoV gastroenteritis outbreak were not avail-
able for patients’ antibody testing, analyses were per-
formed with VLPs of the GII.4-Den Haag_2006b variant,
which share a 93.66 % homology at the amino acid level
with the GII.4-2009 variant.
Norovirus-specific IgA antibody in saliva samples
Microtiter plates were coated GII.4-2006b VLPs at 2 μg/ml
in carbonate/bicarbonate buffer (pH 9.6) and incubated at
4 °C overnight. Plates were washed three times with PBS-T
and blocked for 1 h at 37 °C with PBS-T 3 % BSA. After
blocking, plates were incubated with serial dilutions of sal-
iva samples (from 1/20 to 1/160) in PBS-T 1 % BSA for
1.5 h at 37 °C and NoV-specific IgA antibody was detected
with a secondary anti-IgA human antibody conjugated with
HRP (Sigma) at a dilution of 1/4,000 in PBS-T 1 % BSA for
1 h at 37 °C. As controls, all saliva samples were tested in
parallel in wells coated with BSA at 2 μg/ml. To rule out
nonspecific binding (false positives), boiled saliva samples
were also used as negative controls on wells coated with
VLPs. Wells were washed four times with PBS-T, and
the bound antibody was detected by the addition of
50 μl of o-phenylenediamine (Sigma). The reaction was
stopped at 10 min with 3 M H2SO4, and the absorbance
was read at 492 nm (Multiskan FC spectrophotometer,
Thermo Scientific).
Norovirus-specific IgG antibody titers in serum samples
Purified GII.4-2006b VLPs were used to coat 96-well
polystyrene microtiter plates as described above. After
blocking with PBS-BSA 3 %, plates were incubated with
serial serum dilutions from 1/200 to 1/12,800 diluted in
PBS-T containing 1 % BSA for 1 h at 37 °C. Then HRP-
conjugated anti-human IgG antibody (Santa Cruz
Biotechnology) diluted 1/4,000 was added for 1 h and
the reaction was developed and measured as described
above. A sample was considered positive when its OD
was three times higher than the absorbance value of the
same sample in the specificity control (wells coated with
2 μg/ml of BSA). The titer of each sample was consid-
ered the inverse of the last dilution showing a positive
reaction.
Binding blocking assays
Microtiter plates were coated with saliva at 1/500 in car-
bonate/bicarbonate buffer (pH 9.6) overnight at 4 °C.
Plates were washed three times with PBS-T and blocked
for 1 h at 37 °C with PBS-T 3 % BSA. Plates were then
incubated for 1.5 h with GII.4-2006b VLPs (2 μg/ml)
that had been pre-incubated during 1 h at 37 °C in the
presence of the different sera at serial 2-fold dilutions
from 1/100 to 1/3.200, or with PBS in the negative con-
trol. The mixtures were then added to the saliva-coated
plates and incubated for 1 h at 37 °C. The detection was
performed with the anti-NoV rabbit polyclonal serum at
1/1,000 followed by a secondary HRP-conjugated anti-
rabbit IgG antibody diluted at 1/2,000.
Blocking of VLP binding by the tested sera was deter-
mined by comparing the OD values obtained in wells in
duplicate containing potential blocking reagents against
the control wells (without the blocking steps). Blocking
was considered when the OD value was less than 50 %
of the positive control OD value (ranging from 0.8 to 1.2
OD492 units).
Results
Gastroenteritis outbreak was caused by norovirus
GII.4-New Orleans_2009 variant
In January 2012 three members of a household in Valencia
showed typical symptoms of acute gastroenteritis caused
by NoV 24 h after having been in contact with the index
case. Clinical symptoms were nausea, vomiting, diarrhoea
and fever, which lasted approximately 48 h. One of the
patients had to be taken care of dehydration at the
emergency room.
RT-PCR assay performed on stool samples collected
(n = 3) from two symptomatic patients and from one
asymptomatic individual revealed the presence of NoV
GII.4, specifically the GII.4-New Orleans_2009 variant.
As no other enteric viruses (rotavirus or adenovirus)
were detected by molecular analyses neither entero-
pathogenic bacteria were isolated, it was concluded that
NoV was the etiological agent of this outbreak. The
most relevant result was that the asymptomatic individ-
ual also shed NoVs as his faecal sample was also
positive.
Non-secretor individual (sese) showed no symptoms after
norovirus GII.4-New Orleans_2009 infection
Twenty-five percent (2/8) of the household members
were secretor homozygous (SeSe), 50 % (4/8) secre-
tor heterozygous (Sese) and the remaining 25 % (2/8),
non-secretor (sese). Secretor individuals showed a
Lea+Leb+/Lex-Ley+ phenotype and non-secretor had
the typical Lewis phenotype, Lea+Leb-/Lex+Ley-
(Table 1). Three individuals showed symptoms of
which two were secretor homozygous (SeSe) and
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blood group A, and the other one was heterozygous
(Sese) and blood group O. Non-secretor individuals
showed no symptoms, while at least in one of them
the infection was confirmed by RT-PCR.
Titers of salivary anti-norovirus IgA antibodies
Salivary IgA antibodies to the GII.4-2006b were positive
in all samples. Although the number of samples was too
small to perform statistical analyses, no differences were
found in secretory IgA levels from the two analyzed
groups: secretors and non-secretors (Fig. 1). These re-
sults suggest that non-secretors are also susceptible to
NoV infection even if they do not show clinical symp-
toms, as it was also confirmed by RT-PCR.
Norovirus-specific IgG antibody titers
Three sera were collected and compared with a conva-
lescent serum from a sporadic case of NoV infection,
which was used as the positive control. Of these sera,
two were from secretor individuals that showed symp-
toms and the other one was from an infected non-
secretor without symptoms.
All tested convalescent serum samples showed anti-
body titers higher than 1/100 to the GII.4-2006b variant.
IgG serum titers showed significant differences (P < 0.01)
between secretors and the non-secretor (Fig. 2). Titers
of NoV-specific IgG antibody of 1/12,800 were the high-
est titers found, corresponding to the two symptomatic
infected individuals in their convalescence (14 days p.i.)
and memory (1 year p.i.) serum samples, independently
whether they were homo- or heterozygous for the FUT2
mutation. The serum from the non-secretor individual
showed no changes in its antibody titers, despite having
been in contact with the virus and showing the lowest
antibody titer (Fig. 2).
Blockade of the binding of VLPs to saliva
We examined the blocking capacity of the different
serum samples (both convalescent and memory sera) on
the binding of GII.4-2006b VLPs to saliva from a secre-
tor, blood type O individual. As expected, the binding to
receptors present in the saliva was blocked efficiently by
secretor individual sera, up to 60 % (Fig. 2). On the
other hand, the non-secretor serum sample did not
Table 1 List of the individuals involved in the present study, specifying gender, age, ABO blood group, secretor status based on the
FUT2 gene analysis, Lewis phenotype and faecal NoV shedding detected by RT-PCR
Sample Symptoms Sex Age ABO blood group FUT2 Lewis antigens NoV RT-PCR
1 + F 63 A Se + Se+ Lea+Leb+/Lex-Ley+ +
2 - M 64 A se-se- Lea+Leb-/Lex+Ley- +
3 + F 28 O Se + se- Lea+Leb+/Lex-Ley+ +
4 + M 37 A Se + se- Lea+Leb+/Lex-Ley+ ND
5 - F 8 A se-se- Lea+Leb-/Lex+Ley- ND
6 - M 34 O Se + se- Lea+Leb+/Lex-Ley+ ND
7 - F 39 A Se + se- Lea+Leb+/Lex-Ley+ ND
8 - M 47 B Se + Se+ Lea+Leb+/Lex-Ley+ ND
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Fig. 1 NoV-specific IgA antibody levels. IgA antibody levels against GII.4-Den Haag_2006b NoV VLPs in saliva samples from 6 secretor (left) and 2
non-secretor (right) individuals. The ELISA plates were coated with the NoV VLPs and serial dilutions of saliva samples (1/20 to 1/160) were tested
for NoV-specific IgA
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block the binding at all. The results obtained with the
memory serum showed the same blocking rate as the
corresponding convalescent serum samples.
Discussion
Recent studies have shown that host genetic factors
such as the FUT2 and FUT3 genotypes strongly affect
human susceptibility to NoVs [20]. Due to the lack of
a good animal or in vitro model to investigate NoV
pathogenesis, evidences in this field have been ob-
tained both from volunteers studies and from out-
breaks of natural infections [5], like the outbreak here
reported.
In this outbreak occurred in Valencia in 2012,
although few individuals were affected, different suscep-
tibility to NoV diarrhoea in secretor-positive and
secretor-negative individuals was observed, reinforcing
the idea that non-secretors are naturally protected to
NoV infections [21]. Surprisingly, one of the stool sam-
ples positive for NoV by RT-PCR was from a secretor-
negative individual. This result is highly relevant since it
indicates that NoV replication occurred in the non-
secretor individual but without causing symptoms. This
observation was confirmed with the finding of a high
anti-NoV IgA titer in the saliva of this non-secretor indi-
vidual, similar to the titers in secretor-positive patients,
thus showing that infection had indeed occurred. In the
past we also described a non-secretor that was suscep-
tible to NoV GII.4-Hunter_2004 NoV infection, but in
that case symptoms were also present [14]. In order to
become symptomatically infected (2004 outbreak) or
asymptomatically (2012 outbreak) non-secretors must
display receptors for NoVs, raising the question of what
other receptors, not yet known, may be implicated in
NoV infections. A recent study showed that NoV VLPs
did not colocalize with H or Lewis antigens in epithelial
cells, reinforcing the idea that other receptors are in-
volved in NoV infections [22]. Gangliosids have also
shown to bind NoVs [23]. In addition, enteric bacteria
also seem to play a role in NoV infections acting them-
selves as co-receptors [12, 24, 25]. Another interesting
result is that the secretor-negative individual did not de-
velop IgG antibodies against NoV, in contrast to what it
was observed with the salivary IgA. It can be argued that
the absence of symptoms could be due to a lower infect-
ivity of the virus in the secretor-negative individual, in
whom it only elicited a mucosal immune response. On
the other hand, high IgG titers were found in serum
samples from infected secretors at the outbreak. Sero-
conversion occurred 2 weeks after the infection and the
IgG titers did not decrease 1 year after infection. These
results are relevant, since it has been reported that pre-
vious infections do not protect against subsequent NoV
infections [26]. Our results suggest that this lack of pro-
tection might be due to viral evolution [3, 27–29] in-
stead of a low immune stimulation. In fact, several
seroepidemiologic studies of NoV-specific antibodies in
different populations have been performed [19, 30, 31],
showing high seroprevalence levels and consequently a
good immunogenicity of NoVs. The blocking assays
showed that serum IgG antibodies were able to block
the attachment of VLPs to saliva, reinforcing the idea












































Fig. 2 NoV-specific IgG antibody titers and blocking activity of sera
from members of a household suffering an acute gastroenteritis
outbreak. ELISA plates were coated with NoV VLPs from GII.4-Den
Haag_2006b variant to determine the antibody titer according to
the secretor (Sese or SeSe) or non-secretor (sese) status. The positive
control corresponds to a convalescent serum from another independent
gastroenteritis sporadic case. a The upper panel of the figure represents
the blocking percentage of the convalescent sera (14 days), from
secretors (SeSe and Sese) and non-secretors (sese), that were
tested at serial dilutions 1/100, 1/200, 1/400, 1/800 and 1/1,600
(black to clear grey). A percentage higher of 50 % of inhibition was
considered as blocking activity. b The lower panel shows the IgG
titer against GII.4-Den Haag_2006b VLPs at 2 different times:
14 days (black) and 1 year (grey)
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Conclusions
Although the number of individuals involved in this out-
break was low, limiting the possibility of drawing con-
clusions, our results confirm the hypothesis that
susceptibility to human noroviruses is both dependent
on secretor status of the individuals and on the infecting
NoV strain. We also have shown that the immunity to
NoV lasts for at least 1 year after infection, confirming
that symptomatic infection strongly stimulates an anti-
body response.
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